Charles River Laboratories International, Inc. $CRL Stake Trimmed by Moore Capital Management LP

Moore Capital Management LP lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 91.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,892 shares of the medical research company’s stock after selling 39,342 shares during the period. Moore Capital Management LP’s holdings in Charles River Laboratories International were worth $883,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CRL. Los Angeles Capital Management LLC purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $42,000. Sfam LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $43,000. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $46,000. Finally, Allworth Financial LP grew its holdings in shares of Charles River Laboratories International by 61.3% during the fourth quarter. Allworth Financial LP now owns 350 shares of the medical research company’s stock valued at $70,000 after buying an additional 133 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 0.9%

Shares of NYSE:CRL opened at $289.02 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $13.80 billion, a PE ratio of -59.59, a P/E/G ratio of 3.03 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $303.30. The firm has a fifty day moving average price of $248.22 and a 200 day moving average price of $198.15.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the firm earned $3.12 earnings per share. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CRL shares. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. TD Cowen upped their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Finally, Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research note on Monday, August 10th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.65.

Insider Buying and Selling

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. The trade was a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.